Literature DB >> 9594576

Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3.

L S Phillips1, C I Pao, B C Villafuerte.   

Abstract

The insulin-like growth factors (IGFs) have diverse anabolic cellular functions, and structure similar to that of proinsulin. The distribution of IGFs and their receptors in a wide variety of organs and tissues enables the IGFs to exert endocrine, paracrine, and autocrine effects on cell proliferation and differentiation, caloric storage, and skeletal elongation. IGF-I exhibits particular metabolic responsiveness, and circulating IGF-I originates predominantly in the liver. Hepatic IGF-I production is controlled at the level of gene transcription, and transcripts are initiated largely in exon 1. Hepatic IGF-I gene transcription is reduced in conditions of protein malnutrition and diabetes mellitus, and our laboratory has used in vitro transcription to study mechanisms related to diabetes. We find that the presence of sequences downstream from the major transcription initiation sites in exon 1 is necessary for the diabetes-induced decrease in IGF-I transcription. Six nuclear factor binding sites have been identified within the exon 1 downstream region, and footprint sites III and V appear to be necessary for metabolic regulation; region V probes exhibit a decrease in nuclear factor binding with hepatic nuclear extracts from diabetic animals. IGFs in biological fluids are associated with IGF binding proteins, and IGFs circulate as a 150-kDa complex that consists of an IGF, an IGFBP-3, and an acid-labile subunit. Circulating IGFBP-3 originates mainly in hepatic nonparenchymal cells, where IGF-I increases IGFBP-3 mRNA stability, but insulin increases IGFBP-3 gene transcription. Regulation of IGFBP-3 gene transcription by insulin appears to be mediated by an insulin-responsive element, which recognizes insulin-responsive nuclear factors in both gel mobility shift assays and southwestern blots. Studies of mechanisms underlying the modulation of IGF-I and IGFBP-3 gene transcription, and identification of critical nuclear proteins involved, should lead to new understanding of the role and regulation of these important growth factors in diabetes mellitus and other metabolic disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9594576     DOI: 10.1016/s0079-6603(08)60894-6

Source DB:  PubMed          Journal:  Prog Nucleic Acid Res Mol Biol        ISSN: 0079-6603


  23 in total

Review 1.  Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes.

Authors:  David R Clemmons
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

2.  Elevated HbA1c Is Associated with Altered Cortical and Trabecular Microarchitecture in Girls with Type 1 Diabetes.

Authors:  Deborah M Mitchell; Signe Caksa; Taïsha Joseph; Mary L Bouxsein; Madhusmita Misra
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

3.  Gestational-neonatal iron deficiency suppresses and iron treatment reactivates IGF signaling in developing rat hippocampus.

Authors:  Phu V Tran; Stephanie J B Fretham; Jane Wobken; Bradley S Miller; Michael K Georgieff
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-11-16       Impact factor: 4.310

4.  Perinatal hypoxia-ischemia decreased neuronal but increased cerebral vascular endothelial IGFBP3 expression.

Authors:  W H Lee; G M Wang; X L Yang; L B Seaman; S I Vannucci
Journal:  Endocrine       Date:  1999-10       Impact factor: 3.633

5.  The acid-labile subunit is required for full effects of exogenous growth hormone on growth and carbohydrate metabolism.

Authors:  Iori Ueki; Sarah L Giesy; Kevin J Harvatine; Jin Wook Kim; Yves R Boisclair
Journal:  Endocrinology       Date:  2009-03-19       Impact factor: 4.736

6.  Neonatal and adult human heart tissues from normal subjects and patients with ischemic, dilated or hypertrophic cardiomyopathy express insulin-like growth factor binding protein-3 (IGFBP-3).

Authors:  R Granata; F Broglio; D Migliorino; S Cutrupi; G Baldanzi; M Sireno; A Fubini; A Grazian; E Ghigo; A Pucci
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

Review 7.  Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma.

Authors:  Hyun Lee; So Ri Kim; Youngman Oh; Seong Ho Cho; Robert P Schleimer; Yong Chul Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

8.  Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation.

Authors:  S Weischendorff; K Kielsen; H Sengeløv; K Jordan; C H Nielsen; A E Pedersen; L P Ryder; A Juul; K G Müller
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

9.  Insulin-like growth factor binding protein-3 mediates serum starvation- and doxorubicin-induced apoptosis in H9c2 cardiac cells.

Authors:  R Granata; M De Petrini; L Trovato; R Ponti; N Pons; C Ghè; A Graziani; R J Ferry; G Muccioli; E Ghigo
Journal:  J Endocrinol Invest       Date:  2003-12       Impact factor: 4.256

Review 10.  Unraveling insulin-like growth factor binding protein-3 actions in human disease.

Authors:  Sherryline Jogie-Brahim; David Feldman; Youngman Oh
Journal:  Endocr Rev       Date:  2009-05-28       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.